A large international study found that measuring levels of the blood biomarker p-tau217 can help predict future cognitive decline in healthy older adults. Researchers combined data from six observational studies to track nearly 2,700 participants, discovering that very high biomarker levels correlated with a 38 percent chance of developing cognitive impairment within five years and a 78 percent chance over ten years. Importantly, the protein remained predictive even after accounting for existing amyloid-beta plaques and known genetic risk factors like APOE4.
While the methodological scope is impressive, the practical utility right now is practically nil for someone walking into a clinic. Because there are no approved preventive treatments to alter the disease course for asymptomatic people, a positive result currently offers no actionable medical recourse beyond standard lifestyle advice. It is a genuine scientific advance in biomarker tracking, but one that outruns our current therapeutic toolkit.
more: https://www.sciencedaily.com/releases/2026/10/261029072142.htm
my other side: ivo.blogspot.com
Leave a Reply